<--- Back to Details
First PageDocument Content
Medicine / Immunosuppressants / Immunology / Clinical medicine / Monoclonal antibodies / Cytokines / Therapeutic antibodies / Autoimmune diseases / Infliximab / Anakinra / Adalimumab / Interferon
Date: 2015-08-17 11:45:03
Medicine
Immunosuppressants
Immunology
Clinical medicine
Monoclonal antibodies
Cytokines
Therapeutic antibodies
Autoimmune diseases
Infliximab
Anakinra
Adalimumab
Interferon

EAP Reimbursement Criteria for Frequently Requested Drugs

Add to Reading List

Source URL: www.health.gov.on.ca

Download Document from Source Website

File Size: 1,22 MB

Share Document on Facebook

Similar Documents

Medicine / Immunosuppressants / Immunology / Clinical medicine / Monoclonal antibodies / Cytokines / Therapeutic antibodies / Autoimmune diseases / Infliximab / Anakinra / Adalimumab / Interferon

EAP Reimbursement Criteria for Frequently Requested Drugs

DocID: 1rhhE - View Document

Medicine / Immunology / Clinical medicine / Health care / Immunosuppressants / Biotechnology / Monoclonal antibodies / Immune system / Immunogenicity / Autoimmunity / Infliximab / Arthritis

TABLE OF CONTENTS INTRODUCTION 2

DocID: 1qY7G - View Document

Medicine / Clinical medicine / Health care / Immunology / Immunosuppressants / Monoclonal antibodies / Biotechnology / Immune system / Infliximab / TNF inhibitor / Rheumatology / Biopharmaceutical

JUNE 2015 TABLE OF CONTENTS INTRODUCTION

DocID: 1qDC6 - View Document

Medicine / Clinical medicine / Immunology / RTT / Autoimmune diseases / Immunosuppressants / Rheumatology / Arthritis / Disease-modifying antirheumatic drug / Infliximab / Methotrexate / Psoriatic arthritis

Provincial Drug Programs P. O. Box 2000 Charlottetown PE C1A 7N8Toll Free on PEI) Programmes provinciaux de médicaments

DocID: 1qAvE - View Document

Medicine / Clinical medicine / Immunology / Immunosuppressants / Monoclonal antibodies / RTT / Immune system / Infliximab / TNF inhibitor / Immunogenicity / Arthritis / Adalimumab

TABLE OF CONTENTS INTRODUCTION 2

DocID: 1qs3R - View Document